Patents Assigned to Taiho Pharmaceuticals Co., Ltd.
-
Publication number: 20240122937Abstract: A method of treating a subject with a cancerous tumor exhibiting an inactivating mutation in the PTEN gene including administering to the subject trans-3-amino-1-methyl-3-(4-(3-phenyl-5H-imidazo[1,2-c]pyrido[3,4-e][1,3]oxazin-2-yl)phenylcyclobutanol or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 27, 2022Publication date: April 18, 2024Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Karim BENHADJI, Osamu TAKAHASHI
-
Patent number: 11918562Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).Type: GrantFiled: September 30, 2021Date of Patent: March 5, 2024Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Hiromi Muraoka, Akira Kanoh
-
Patent number: 11883404Abstract: It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 21, 2019Date of Patent: January 30, 2024Assignee: Taiho Pharmaceuticals Co., Ltd.Inventors: Akihiro Miura, Hiroshi Sootome, Junya Iwasaki
-
Patent number: 11883410Abstract: This invention relates to a preventive and/or therapeutic agent for sarcopenia, comprising a prostaglandin D2 production inhibitor as an active ingredient.Type: GrantFiled: April 18, 2019Date of Patent: January 30, 2024Assignees: National University Corporation Tokyo University of Agriculture and Technolgy, Taiho Pharmaceutical Co., Ltd.Inventors: Masaki Inada, Daisuke Kajiwara
-
Publication number: 20240025910Abstract: An object to be solved of the present invention is to provide a brain-penetrable antitumor agent showing an excellent brain penetration property and RET inhibitory activity. The present invention provides brain-penetrable antitumor agent including a compound represented by Formula (I) below or a salt thereof as an active ingredient: wherein R1, R2, and R3 are as described in Specification.Type: ApplicationFiled: November 18, 2021Publication date: January 25, 2024Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Isao MIYAZAKI, Satoru IGUCHI, Kentaro WAKAYAMA
-
Publication number: 20240000791Abstract: The present invention relates to compositions and methods for treating patients with cancer having a RET gene abnormality comprising administering HM06/TAS0953, for example patients with non-small cell lung cancer (NSCLC), and that may also have brain and/or leptomeningeal metastases, or another solid tumor; where the patient is administered an effective amount of HM06/TAS0953, where the HM06/TAS0953 can be formulated in a composition and administered orally in a single or multiple doses; and where the patients may have previously received and/or have developed resistance to another RET-selective or multi-kinase inhibitor.Type: ApplicationFiled: November 18, 2021Publication date: January 4, 2024Applicants: Helsinn Healthcare SA, Taiho Pharmaceutical Co., Ltd.Inventors: Emanuela Lovati, Ruben Giorgino, Simona Doria, Claudio Giuliano, Annalisa Bonifacio, Miharu Igarashi, Isao Miyazaki, Masanori Kato, Alberto Bernareggi
-
Patent number: 11857513Abstract: An antitumor agent comprising a compound selected from the group consisting of Compounds A to D described in the specification, or a salt thereof, for treating a malignant tumor patient expressing EGFR having exon 20 insertion mutation.Type: GrantFiled: October 31, 2017Date of Patent: January 2, 2024Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Kazutaka Miyadera, Yoshimi Aoyagi, Shinichi Hasako
-
Publication number: 20230390251Abstract: The present invention provides a pharmaceutical composition for preventing and/or treating an RNR-related disease in a patient in need thereof, wherein the pharmaceutical composition comprises 5-chloro-2-(N-((1S,2R)-2-(6-fluoro-2,3-dimetylphenyl)-1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl)sulfamoyl)benzamide or a salt thereof, and is administered to the patient on an intermittent administration schedule for two weeks comprising dosing 1 to 5 days per week. The present invention also provides a method of treating an RNR-related diseases in a patient in need thereof, the method comprising administering an effective amount of 5-chloro-2-(N-((1S,2R)-2-(6-fluoro-2,3-dimetylphenyl)-1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl)sulfamoyl)benzamide or a salt thereof to the patient on an intermittent administration schedule for two weeks comprising dosing 1 to 5 days per week.Type: ApplicationFiled: September 15, 2021Publication date: December 7, 2023Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki UENO, Takuya HOSHINO
-
Patent number: 11833151Abstract: The object of the present invention is to improve the dissolution and the absorption of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl-1-pyrrolidinyl)-2-propen-1-one effective as an antitumor agent from a pharmaceutical formulation comprising the same. Provided is a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl-1-pyrrolidinyl)-2-propen-1-one in combination with sodium alkyl sulfate having an alkyl group containing 10 to 18 carbon atoms, in particular, with sodium lauryl sulfate.Type: GrantFiled: March 18, 2019Date of Patent: December 5, 2023Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Kenji Kusumoto, Sadahiro Miyamura
-
Publication number: 20230331730Abstract: A crystal of 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide (compound (I)), and a crystal thereof with an acid (salt crystal or co-crystal) are provided. There are provided: a type II crystal of compound (I) with fumaric acid, having characteristic peaks at three or more diffraction angles (2? ± 0.2 °) selected from 5.5°, 6.8°, 9.3°, 13.4°, 15.3°, 16.3°, 18.5°, 19.8°, 22.0°, and 24.5° in a powder X-ray diffraction spectrum; a (free-form) type II crystal of compound (I) having characteristic peaks at three or more diffraction angles selected from 8.3°, 14.8°, 17.3°, 18.0°, 19.1°, 20.3°, 21.0°, 22.5°, 23.0°, and 26.2° in a powder X-ray diffraction spectrum; a (free-form) type I crystal of compound (I) having characteristic peaks at three or more diffraction angles selected from 9.9°, 11.7°, 13.2°, 17.7°, 18.1°, 18.8°, and 20.Type: ApplicationFiled: July 14, 2021Publication date: October 19, 2023Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki NAKAMURA, Hiroyoshi YAMANAKA, Takahiro ASAI
-
Patent number: 11786534Abstract: The present invention provides a novel compound inhibiting EGFR or a salt of the compound. According to one embodiment of the present invention, provided is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 14, 2020Date of Patent: October 17, 2023Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Fuyuki Yamamoto, Takashi Mizutani, Hidefumi Kasuga, Hirokazu Fuchida, Shoki Hara, Yu Kobayakawa, Yoshio Ogino
-
Publication number: 20230322812Abstract: An object of the present invention is to provide a crystal of compound 1, which is useful as an antitumor agent, the crystal being stable, excellent in oral absorbability, highly chemically pure, and suitable for mass production. The present invention provides a crystal of compound 1 that exhibits an X-ray powder diffraction spectrum containing, at diffraction angles 2?±0.2°, characteristic peaks of at least 3 characteristic peaks selected from the group consisting of 5.8°, 9.8°, 12.2°, 14.0°, 15.3°, 21.1°, and 27.6°.Type: ApplicationFiled: August 24, 2021Publication date: October 12, 2023Applicants: TAIHO PHARMACEUTICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Takashi MITA, Daisuke TAKEDA
-
Publication number: 20230295068Abstract: Provided are a compound represented by formula (I) or a salt thereof, a nerve growth promoter containing the compound or a salt thereof as an active ingredient, a pharmaceutical composition containing the compound or a salt thereof, a therapeutic agent for neurodegenerative diseases containing the compound or a salt thereof as an active ingredient, a therapeutic agent for amyotrophic lateral sclerosis containing the compound or a salt thereof as an active ingredient, a therapeutic agent for pain containing the compound or a salt thereof as an active ingredient, and a therapeutic agent for lower urinary tract dysfunction containing the compound or a salt thereof as an active ingredient.Type: ApplicationFiled: August 6, 2021Publication date: September 21, 2023Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Kazuhiko SHIGENO, Takahisa NOMA, Atsushi HAKOZAKI
-
Publication number: 20230285397Abstract: Provided is a therapeutic agent for a disease associated with EGFR, the agent comprising a compound that has EGFR inhibitory activity and has brain penetration properties as an active ingredient. The present invention provides a compound represented by the formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the present specification, or a salt thereof, and a therapeutic agent for a disease associated with EGFR, the agent comprising a compound represented by the following formula (I), or a salt thereof as an active ingredient.Type: ApplicationFiled: July 14, 2021Publication date: September 14, 2023Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventor: Kei OGUCHI
-
Publication number: 20230255972Abstract: Provided is a tumor treatment method using a pyrimidine compound or a salt thereof. An antitumor agent that contains a pyrimidine compound represented by general formula (I) or a salt thereof, said antitumor agent being to be administered in combination with another antitumor agent. (In the formula, R1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having, as a substituent(s), one to five C1-C4 alkoxy groups or one to five fluorine atoms, or a C1-C6 alkoxy group; R3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having, as a substituent(s), one to five fluorine atoms; R4 represents a hydrogen atom or a C1-C4 alkyl group; and R5 represents a phenyl group optionally having one to three substituents selected from fluorine atoms and chlorine atoms.Type: ApplicationFiled: July 14, 2021Publication date: August 17, 2023Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Kei OGUCHI, Yuki SHIKATA, Junya IWASAKI
-
Publication number: 20230255903Abstract: The present invention addresses the problem of providing a voiding symptom therapeutic agent for lower urinary tract disorders accompanied by residual urine. The present invention provides a voiding symptom therapeutic agent for lower urinary tract disorders with a residual urine volume of 50 mL or more, the therapeutic agent containing 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexen-1-one or a salt thereof as an active ingredient.Type: ApplicationFiled: July 2, 2021Publication date: August 17, 2023Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventor: Makoto NAGAOKA
-
Patent number: 11701359Abstract: An antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of G719X mutation of exon 18, E709X mutation of exon 18, and L861X mutation of exon 21, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof.Type: GrantFiled: August 31, 2018Date of Patent: July 18, 2023Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Naomi Abe, Shinichi Hasako
-
Patent number: 11696917Abstract: To provide a method for treating cancer using a pyrazolo[3,4-d]pyrimidine compound or a salt thereof. The present invention provides an antitumor agent comprising a pyrazolo[3,4-d]pyrimidine compound of formula (I) wherein X, Y, Z1, Z2, Z3, Z4, W, n, R1, R2, and R3 have meanings as defined in the present specification, or a salt thereof and other antitumor agent(s) for combined administration.Type: GrantFiled: February 27, 2018Date of Patent: July 11, 2023Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Hiroki Irie, Kei Oguchi, Yayoi Fujioka
-
Patent number: 11690843Abstract: It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 3, 2017Date of Patent: July 4, 2023Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Akihiro Miura, Hiroshi Sootome
-
Patent number: 11690838Abstract: Provided are a therapeutic agent and a pharmaceutical composition exerting an excellent prophylactic or therapeutic effect on fibrosis and symptoms associated with fibrosis. The therapeutic agent for fibrosis comprises 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof as an active ingredient.Type: GrantFiled: October 29, 2021Date of Patent: July 4, 2023Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventor: Akio Fujioka